QuidelOrtho Corp (QDEL) stock
QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/3063% below fair value
$9.87−0.34 (-3.33%)
Close on Nov 17, 2026Market cap $676.84MP/E –Yield –
QuidelOrtho ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
QuidelOrtho's ebitda for the twelve months ending Sep 27, 2026 was $334.30M. For fiscal 2025 it was -$477.20M. The highest annual figure on record is $1.13B in fiscal 2022.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | -$477.20M | – |
| FY2024 | Dec 29, 2024 | -$1.51B | -352.8% |
| FY2023 | Dec 31, 2023 | $596.30M | -47.1% |
| FY2022 | Jan 1, 2023 | $1.13B | +17.6% |
| FY2021 | Jan 2, 2022 | $958.70M | -13.6% |
| FY2020 | Jan 3, 2021 | $1.11B | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 27, 2026 | $112.10M | – |
| Q2 FY2026 | Jun 28, 2026 | $94.90M | – |
| Q1 FY2026 | Mar 29, 2026 | $81.10M | -41.9% |
| Q4 FY2025 | Dec 28, 2025 | $46.20M | +419.1% |
| Q3 FY2025 | Sep 28, 2025 | -$592.70M | -562.7% |
| Q2 FY2025 | Jun 29, 2025 | -$70.40M | – |
| Q1 FY2025 | Mar 30, 2025 | $139.70M | – |
| Q4 FY2024 | Dec 29, 2024 | $8.90M | -94.3% |
| Q3 FY2024 | Sep 29, 2024 | $128.10M | -8.1% |
| Q2 FY2024 | Jun 30, 2024 | -$1.40M | -101.6% |
| Q1 FY2024 | Mar 31, 2024 | -$1.64B | -868.5% |
| Q4 FY2023 | Dec 31, 2023 | $155.50M | -23.4% |
| Q3 FY2023 | Oct 1, 2023 | $139.40M | -13.4% |
| Q2 FY2023 | Jul 2, 2023 | $87.60M | -31.1% |
| Q1 FY2023 | Apr 2, 2023 | $213.80M | -66.4% |
| Q4 FY2022 | Jan 1, 2023 | $203.10M | -48.2% |
| Q3 FY2022 | Oct 2, 2022 | $161.00M | -45.3% |
| Q2 FY2022 | Jul 3, 2022 | $127.20M | +257.3% |
| Q1 FY2022 | Apr 3, 2022 | $636.00M | – |
| Q4 FY2021 | Jan 2, 2022 | $392.10M | – |
| Q3 FY2021 | Oct 3, 2021 | $294.50M | – |
| Q2 FY2021 | Jul 4, 2021 | $35.60M | – |
See a number that looks wrong?